Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma
Trial details
- Registry ID
- NCT02446093
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as AdV-tk; CAN-2409
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic AdenocarcinomaNCT02446093 | CADL | Phase 2 | Unknown | 2025-12Estimated |
| CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLCNCT04495153 | CADL | Phase 2 | Active not recruiting | 2024-12-31Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |